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CASPR2-antibodies led to permanent behavioral, cellular, 
and synaptic abnormalities. These findings support a patho-
genic role for maternal antibodies in human neurodevelop-
mental conditions, and CASPR2 as a potential target.
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Introduction
In the later part of the 19th century, Paul Ehrlich showed, 
by a series of elegant experiments on rodents, that immu-
nity is transferred from the mother to her fetus [31]. In 
mammals, this task is undertaken by the neonatal Fc 
receptor (nFcR) that binds to maternal Immunoglobulin G 
(IgG) and transposes it into the fetal circulation [28]. This 
maternally acquired IgG is thought to provide the new-
born with short-term adaptive immunity, until the immune 
system has fully developed. However, both protective and 
potentially pathogenic antibodies (i.e., antibodies that 
could target fetal/neonatal proteins) are transferred through 
this mechanism. This fact is now well established, through 
animal and human data, in various neonatal autoimmune 
diseases [21].
A similar mechanism was proposed in autism and 
other neurodevelopmental disorders [36], and for review, 
see [10]. The hypothesis is that the passage of a mater-
nal antibody targeting central nervous system (CNS) pro-
teins across the placenta and through a partly permissive 
fetal blood–brain barrier results in permanent abnormali-
ties in the developing brain. A subgroup of mothers of 
children with autism spectrum disorders was shown to 
have antibodies targeting fetal brain proteins important in 
Abstract Gestational transfer of maternal antibodies 
against fetal neuronal proteins may be relevant to some neu-
rodevelopmental disorders, but until recently there were no 
proteins identified. We recently reported a fivefold increase 
in CASPR2-antibodies in mid-gestation sera from mothers 
of children with intellectual and motor disabilities. Here, 
we exposed mice in utero to purified IgG from patients 
with CASPR2-antibodies (CASPR2-IgGs) or from healthy 
controls (HC-IgGs). CASPR2-IgG but not HC-IgG bound 
to fetal brain parenchyma, from which CASPR2-antibodies 
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social interaction deficits, abnormally located glutamater-
gic neurons in layers V–VI of the somatosensory cor-
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decrease in glutamatergic synapses in layers of the prefron-
tal and somatosensory cortices. Thus, in utero exposure to 
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neurodevelopment in a previous study [4], but the identified 
targets were intracellular proteins, and are unlikely to be a 
primary cause.
By contrast, CASPR2 (contactin-associated protein-2) 
is an appropriate neuronal-surface target for maternal 
antibodies that could alter neurodevelopment. CASPR2 
is clearly important in neuronal migration, as highlighted 
by the occurrence of cortical dysplasia in patients with an 
autism spectrum disorder and epilepsy due to CNTNAP2 
(the gene encoding for CASPR2) homozygous mutations 
[33]. Mutations have also been identified in other neurode-
velopmental disorders associated with psychosis, learn-
ing disability, or speech impairment [26]. Furthermore, 
CASPR2-antibodies are potentially pathogenic in adult 
patients with several neurological disorders, such as neuro-
myotonia, limbic encephalitis, or Morvan’s syndrome [13].
Recently, in a study of coded gestational samples, we 
found CASPR2-antibodies in 8 (4.4%) of 181 mothers of 
children with a diagnosis of mental retardation or other 
disorders of psychological development compared with 3 
(0.9%) of 347 control mothers (P  =  0.01) [8]. Others [5] 
have also reported CASPR2-antibodies in a high percent-
age (37%) of selected sera (brain-reactive) in a subgroup of 
mothers of autistic children compared with 8–12% in the 
control groups, and have explored the consequences of in 
utero exposure to a monoclonal CASPR2-reactive antibody 
derived from one mother of a child with autism in a mouse 
model.
To explore the long-term sequelae of in utero exposure 
to these antibodies, we used our established mouse mater-
nal-to-fetal transfer model [9, 15] using human IgG prepa-
rations from two patients with CASPR2-antibody encepha-
litis and from three healthy individuals. We systematically 
studied the maternal-to-fetal transfer of the antibodies, their 
binding to embryonic mouse brain, and the behavioral and 
neuropathological consequences.
Materials and methods
Human samples and IgG purification
Plasma exchange samples (obtained during periods of 
disease exacerbation) of two male patients with CASPR2-
positive encephalitis (CASPR2-IgG) and sera kindly 
donated from three healthy age- and sex-matched indi-
viduals (HC-IgG) were used in this animal model. Writ-
ten informed consent was obtained from both patients 
and healthy controls. Human IgG was purified through 
the ammonium sulphate precipitation method to avoid 
possible damage to the Fc domains during elution from 
Protein-G columns [17]. The preparations were exten-
sively dialyzed against Hartmann’s solution, concentrated 
by dialysis against polyethylene glycol, and filter-steri-
lized. IgG concentration was determined using a com-
mercially available human IgG radial immunodiffusion 
kit (The Binding Site, Birmingham, UK). Antibody levels 
were determined using a live cell-based assay expressing 
EGFP-tagged human CASPR2, as previously reported 
[13]. A summary of the details of the patients, plasma 
antibody titers, number of injected dams, and injected 
material for each experiment are provided in Online 
Resource 1 and 2.
Specificity of binding to CASPR2 was assessed for 
all samples used. The two CASPR2-antibody patients’ 
IgGs (CASPR2-IgGs) were shown to bind strongly to 
the surface of live cells expressing EGFP-tagged human 
CASPR2, to live (unfixed) rodent hippocampal neurons, 
and to sections of fixed mouse brain from wild-type mice. 
There was no binding to live hippocampal neurons or to 
brain sections from Cntnap2 knockout mice (B6.129(Cg)-
Cntnap2tm1Pele/J; Jackson Laboratory), a homozygous 
knockout mouse for the gene encoding CASPR2, con-
firming that there was absent or limited reactivity with 
other neuronal targets in the CASPR2-IgG preparations 
(Fig. 1a, top panels). Healthy control-IgG 1-3 did not bind 
to human CASPR2-EGFP-transfected cells, mouse live 
hippocampal neurons, or brain tissue sections (Fig.  1a, 
bottom panels). Plasma CASPR2-antibodies from both 
patients bound to wild-type fetal brain tissue at E18.5 
(Fig.  1b). In the isocortex, human IgG from CASPR2-
antibody patients was detected around the neuronal cell 
body and dendritic processes, extending radially to the 
deeper layers, as already reported for CASPR2 expression 
[11]. This staining was absent in the Cntnap2 knockout 
mice when CASPR2 or HC plasma was used.
Animals
Crl: MF1 outbred female mice (20–25  g) and adult 
male breeders of the same strain were purchased from 
a licensed breeding establishment (Charles River, Kent, 
UK Ltd). The animals were housed and mated in the 
Biomedical Services Unit at the John Radcliffe Hospital 
under standard laboratory conditions (ad libitum access 
to food and water; 12:12 light:dark cycle with lights on at 
7 am). Establishment of pregnancy relied on detection of 
vaginal coagulant plugs the morning after mating. E0.5 
was defined as the day on which the plug was detected 
and P0 as day of delivery. All in vivo experiments, with 
IgG preparations coded and investigators blinded, were 
performed in accordance with the United Kingdom Home 
Office Animals in Scientific Procedures Act (1986) and in 
accordance with institutional guidelines under HO PPL 
40/3581.
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Experimental design
There were three main experiments (Experiment 1–3). In 
each, dams were tagged and randomized between cages, 
and injected intraperitoneally with independently coded 
purified human IgG preparations (15–20  mg/day; volume 
1–2 ml) daily from E12.5 until E18.5 or until the time of 
culling [15], as indicated in Fig. 2a.
Experiment 1 assessed the maternal-to-fetal transfer of 
antibodies. Fifteen milligrams of one CASPR2-IgG was 
injected daily into four pregnant dams from E12.5 onwards. 
Dams were sacrificed at E14.5, E16.5, E18.5, and P0 (one 
dam per time point) by  CO2 anaesthesia, followed by car-
diac puncture for blood collection. The dams were then dis-
sected and the uteri removed. Fetuses were dissected out of 
their membranes, separated from the placenta, and washed 
in saline. Fetuses/pups were sacrificed by decapitation, and 
fetal blood was collected by suspending the trunk. Blood 
was pooled from the fetuses/pups of each litter and the 
sera separated and stored at −20 °C. Total human IgG was 
determined by quantitative western blotting and CASPR2-
antibodies detected by a live cell-based assay as above 
(details in Online Resource 3).
Experiment 2 examined the embryos at E18.5 after 
injection of three dams per group with 20 mg IgG per day. 
Dissected fetuses were decapitated and flash frozen in ice-
cold isopentane. Twelve micrometer sagittal sections of 
the entire head were obtained from 3 fetuses per treatment 
group, from 3 different litters, and used for immunohisto-
chemistry (IHC)/immunofluorescence. Details are provided 
in Online Resource 3.
Brain sections (1 in 10 series) from one embryo per 
litter were stained for total human IgG. In the same slide 
containing 4 consecutive sections, the two bottom sections 
were briefly washed 3 times in phosphate buffer saline 
(PBS), while the two upper sections were unwashed. All 
sections were then fixed with 4% paraformaldehyde (PFA) 
for 10 min. After 3 washes in PBS, sections were incubated 
with CF488A anti-human IgG (Biotium, 20022) at 1:500 
overnight at 4 °C. The following day, sections were washed 
3 times in PBS and incubated with rabbit anti-von Wille-
brand factor (VWF; Millipore, AB7356, 1:250) for 3 h at 
room temperature (RT), followed by incubation with goat 
anti-rabbit Alexa Fluor 568 secondary for 1 h at RT. After 
washing 3 times in PBS, coverslips were mounted using 
fluorescent mounting media containing DAPI (1:1000). 
Sections were visualized using a Leica DM 2500 immuno-
fluorescence microscope. For quantitative analysis of the 
mean fluorescent intensity, 3 photomicrographs were taken 
from the isocortex in 3 different sections from 3 embryos/
Fig. 1  Specificity of CASPR2-IgG. a CASPR2-IgG detected by 
anti-human IgG (red) binds to HEK cells expressing EGFP-tagged 
human CASPR2 (green), live hippocampal neurons (neuronal marker: 
MAP2, red; CASPR2-IgG, green), and tissue sections from wildtype 
but not from Cntnap2 knockout mouse brains. HC-IgG shows no 
binding to CASPR2-expressing HEK cells, wild-type hippocampal 
neurons, or wild-type brain sections. b CASPR2 plasma IgG (red) 
bind to tissue sections from E18.5 wildtype but not from Cntnap2 
knockout mouse brains. HC plasma IgG (red) shows no binding to 
sections from E18.5 wild-type mouse brain. Representative images 
using material from CASPR2 patient 1 and HC 1. Scale bar (white): 
25 µm; scale bar (black): 3 mm
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treatment group (27 photomicrographs/treatment group). 
Mean fluorescence intensity was then assessed for each 
photomicrograph using ImageJ. Results were plotted for 
both individual photomicrographs and for the mean results 
from each pup.
Human IgG was eluted from CASPR2-IgG and HC-IgG 
exposed embryos (3 embryos per group) following a pre-
viously described protocol [6] and as detailed in Online 
Resource 3.
Experiment 3 looked at the long-term effects of mater-
nal–fetal transfer. Dams were injected daily from E12.5 to 
E18.5 with CASPR2-IgG from two patients and HC-IgG 
from two donors (4 dams per treatment group; IgG con-
centration 20 mg/day; volume 1–2 mL/day) and allowed to 
deliver. At P0 (usually the morning following delivery), the 
number of live and dead pups was counted and the litter left 
undisturbed with the dam for 24 h. At P1, to ensure equal 
maternal interactions, six pups were randomly selected 
from each litter and individually tattooed for coded behav-
ioral testing. During these procedures, the dam was left in 
the home cage and was placed in the testing room for habit-
uation. The remaining pups from that litter were culled by 
decapitation and blood was pooled for antibody testing.
Behavior analysis of the offspring
Behavioral experiments were conducted at the times indi-
cated in Fig.  2b and c. Behavioral testing of the neonatal 
pups was performed from postnatal days 1–21 and con-
sisted of evaluation of developmental milestones using the 
Fig. 2  Experimental design and behavioral testing. a Experimental 
design. Experiment 1: Crl:MF1 dams (n = 4) were injected intraperi-
toneally (IP) with 15 mg of CASPR2-IgG daily from E12.5. One dam 
and offspring were sacrificed at each time point (E14.5, E16.5, E18.5, 
and P0) and sera collected for human IgG quantification and CASPR2-
antibody testing. Experiment 2: Crl:MF1 dams (n  =  3/group) were 
injected IP with 20 mg of the two CASPR2-IgGs and three HC-IgGs 
or equal volumes of saline from E12.5 until E17.5. All dams and off-
spring were sacrificed at E18.5 and embryonic tissue collected for 
analysis. Experiment 3: Crl:MF1 dams (n = 4/group) were injected IP 
with 20 mg of two CASPR2-IgGs and two HC-IGs from E12.5 until 
E18.5. At P1, litters were reduced to 6 pups. Neonatal assessment was 
conducted from P1 to P21 and adult assessment from 4 to 10 months 
of age. At 12  months, animals were sacrificed and brains dissected 
for histology. b Behavioral assessment. Neonatal testing performed 
as indicated in the table and continued daily until pup reached crite-
rion on 2 consecutive days. The maternal retrieval (MR) test was per-
formed at P6. Testing was done in all pups [n = 24 (4 litters)/group]. 
c Adult testing performed as indicated, and performed in half of the 
cohort (12 animals/treatment group), with the exception of the loco-
motor activity and the T-maze spontaneous alternation test done in all 
animals (1 HC-IgG mouse deceased for non-experimental reasons), 
and the reciprocal social interaction test done in all pairs meeting 
weight-matching criteria (n = 15 CASPR2-IgG pairs; n = 6 HC-IgG 
pairs). LMA locomotor activity, EPM elevated plus-maze, LDB light–
dark box, RTR accelerating rotarod, T-SA T-maze spontaneous alterna-
tion, NTG nesting, 3C-SI 3-chamber social interaction, R–SI reciprocal 
social interaction, OLF olfactory test
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modified Fox battery [12], which assesses physical matu-
ration readouts, neurological reflexes, and motor coordina-
tion, and a maternal retrieval test, as described in Online 
Resource 3.
A battery of behavioral tests was performed in the mice 
when adults (>4  months old, mainly 4–8  months). Tests 
performed assessed locomotor activity, motor coordina-
tion, anxiety, short-term memory, social interaction/activi-
ties and non-social behaviors, and olfaction (see Online 
Resource 3). All behavioral tests and subsequent histologi-
cal analyses were performed blinded to treatment group.
Morphological and morphometric analyses
After behavioral testing, six animals per treatment group 
(3 males and 3 females) were randomly selected for histo-
logical analysis at 12 months. Mice were deeply anaesthe-
tized with Isoflurane followed by pentobarbital injection 
(100 mg kg−1 ip) and transcardially perfused with 100 ml 
of PBS followed by 50  ml of ice-cold 4% PFA in 0.1  M 
phosphate buffer. Brains were removed and post-fixed 
for 24 h at RT before transferring to 30% sucrose in PBS. 
Using a freezing stage sledge microtome, free-floating cor-
onal sections were obtained in 15 series at a thickness of 
50 μm/section.
The detailed methods for cortical layer measurements 
and immunohistochemistry for neurons and microglia are 
given in Online Resource 3. CUX-1-positive cells in lay-
ers V and VI of the somatosensory cortex were counted 
in the coronal slices at Bregma—1.46  mm. 16 images 
(418.4 μm × 418.4 μm) were taken per mouse using a Zeiss 
confocal microscope in one plane (depth = 5 μm) on 50 μm 
coronal sections incubated in fluorescently tagged antibod-
ies. At least 350 cells were counted per brain using Fiji cell 
counter and an average density (cells/mm2) per case was 
obtained.
Quantification of activated microglia (defined as CD68/
Iba-1 positive cells) was performed in layers I, II–III, 
and V–VI in the infralimbic and prelimbic areas (Bregma 
+1.42 mm) and in layers I, II–IV, and V–VI in the soma-
tosensory cortex (Bregma −1.46  mm). The z-stack area 
was 174.3  μm × 174.3  μm for the prefrontal areas and 
111.15 μm × 111.15 μm for the somatosensory areas. The 
z-step/interval was 2 µm and microglial cells were counted 
within a 50 µm depth. Four z-stacks per layer were imaged 
in the infralimbic and prelimbic areas and six z-stacks per 
layer in the somatosensory area. An average density was 
obtained (cells/mm3) in both hemispheres. At least 100 
cells per layer were counted.
Microglial morphology was assessed in 24 confocal 
z-stacks/case at 40× magnification (28 μm thickness with 
imaging every 2  μm) detecting fluorescence in IBA-1 
expressing cells in layers of the somatosensory cortex. 
Minimum resolution of 512  ×  512 was used and with a 
line averaging of 4 to allow for a detailed assessment of 
microglial cells in each group. A macro (details in Online 
Resource 3) written for use in Fiji (Image Analysis soft-
ware) was used to obtain in each stack a clear representa-
tion of the cell body and processes of 101 microglial cells 
per group. Soma size (μm2) and number of ramifications 
per cell were recorded manually in Fiji.
Immunohistochemistry for synaptic proteins was per-
formed using a guinea pig anti-synaptophysin antibody 
(Frontiers Institute, Syn-GP-Af300; 1:200) and a rab-
bit anti-PSD95 antibody (Frontiers Institute, PSD95-Rb-
Af628; 1:200) to identify the presynaptic zone and the 
post-synaptic density of asymmetric glutamatergic syn-
apses, respectively. For GluA1/PSD95 immunofluores-
cence, a rabbit anti-GluA1 antibody (Frontiers Institute, 
GluA1-Rb-Af692; 1:200) and a guinea pig anti-PSD95 
antibody (Frontiers Institute PSD95-GP-Af660; 1:200) 
were used. 50 μm sections were air-dried for 48 h, rehy-
drated in PBS for 15  min, and then placed in a solution 
of 50% ethanol: PBS for 30  min at RT. Sections were 
subsequently dipped in double distilled  H20 to wash off 
the ethanol then in citrate-EDTA buffer (10  mM citric 
acid, 2  mM EDTA, 0.05% Tween-20 at pH 6.2) prior to 
a heat-mediated antigen retrieval step in citrate buffer for 
10 min. Proteinase K treatment (4 μg/ml) for 10 min fol-
lowed by a 10  min pepsin treatment (1  mg/ml) at 37  °C 
in 0.2 M HCl solution were required to unmask antigenic 
epitopes. Sections were then incubated with primary anti-
bodies diluted in PBS-Azide-Triton-X-100 (0.3%) for 3 
days at RT, and washed and incubated overnight with 
anti-guinea pig (1:500) and anti-rabbit (1:500) secondary 
antibodies from Life Technologies conjugated to Alexa 
Fluor 555 and 488 fluorophores, respectively, and con-
centrated DAPI at 1:50,000 in PBS. Sections were sub-
sequently washed and mounting medium added. Two 
z-stacks measuring 66.11 × 66.19 × 6 μm with a voxel size 
of 0.04 × 0.04 × 0.1 μm (XYZ) were taken in each layer of 
the infralimbic, the prelimbic, and the somatosensory cor-
tices in both hemispheres. This resulted in 60 optical sec-
tions available to quantify the number of PSD95-positive 
profiles and GluA1-positive profiles (synaptic contained 
in PSD95-positive profiles and extra-synaptic negative for 
PSD95) and at least 2000 puncta per layer were quantified. 
All image processing and analyses was performed in Fiji. 
To process images for quantification of synaptic profiles, 
first z-stacks were deconvolved using the WPL deconvo-
lution algorithm in the Parallel Iterative Deconvolution 
ImageJ plugin [38] based on the Iterative Deconvolve 
3D algorithm [27] utilizing a theoretical 3D point spread 
function generated in PSF Lab [19]. Image stacks were 
then filtered with a 3  ×  3 median filter and thresholded 
using the OTSU method [20] to obtain accurate binary 
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representations of positive profiles. To assess synapse pro-
files, individual z-slices separated by 0.4 μm were isolated 
and positive puncta profiles were analyzed using the Ana-
lyze Particles algorithm in Fiji. Puncta profile counts in 
each layer were averaged over two sections per animal, and 
plotted as profile counts per 100 μm2.
NeuN-positive cells were quantified by layer in the 
coronal slice at Bregma—1.46 mm. The z-stack area was 
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174.3 μm × 174.3 μm for the medial prefrontal areas and 
111.15  μm  ×  111.15  μm for the somatosensory areas. 
The z-step/interval was 5  μm and NeuN-positive cells 
were counted within eight optical sections through the 
50-μm stack. Four z-stacks per layer were imaged in the 
infralimbic, prelimbic, and somatosensory areas. An 
average density was obtained (cells/mm3) in both hemi-
spheres. For layer I, at least 100 cells were counted; 
for the remaining layers, at least 400 cells/layer were 
counted.
Statistics
Results were analyzed by independent samples t test 
or a Mann–Whitney U test, depending on data distri-
bution, or by repeated-measures/two-way ANOVA. A 
Holm–Sidak correction was applied to correct for mul-
tiple comparisons when appropriate. A statistically sig-
nificant result was considered if p < 0.05. Analysis was 
performed in IBM SPSS statistics version 21.0 (SPSS 
Inc., Chicago, USA). Graphs were plotted using Graph 
Pad prism version 6 (GraphPad software, San Diego, 
California, USA). To account for intra-litter effects dur-
ing the neonatal period, the means for each litter were 
used in statistical comparisons, rather than the data from 
individual pups. In adult animals, unless mentioned oth-
erwise, data represent the mean ± SEM of average val-
ues derived from individual animals.
Results
Human IgG and specific CASPR2‑antibodies are 
transferred from maternal to fetal circulation and brain 
parenchyma (Experiment 1 and 2)
The maternal human total IgG levels varied between 3 and 
7 mg/ml over the 7 days of transfer (E12.5–E18.5), while 
human IgG in the fetal sera did not exceed 0.4  mg/ml at 
the end of gestation (i.e., about 10% of maternal levels at 
that time; Fig. 3a, left panel). Nevertheless, the CASPR2-
antibodies were clearly present in the pool of fetal sera, 
with titers at the end of gestation of 1:40 in Experiment 1 
(Fig. 3a, left panel) and 1:100–1:200 in the pups in Experi-
ments 2 and 3 (data not shown), where higher titer IgG 
preparations were used.
To see whether human IgG could be detected in the 
brain tissue of the fetal brains shortly before delivery (Exp 
2), three dams per treatment group were injected with HC-
IgG or CASPR2-IgG (patient 1, 20 mgs/day) from E12.5 
to E17.5, and the dams culled at E18.5. Visual inspection 
of all embryos prior to culling showed no gross malfor-
mations in the litters of either treatment group, and there 
were no gross brain morphological abnormalities on Nissl 
staining of the embryo heads after snap-freezing (Online 
Resource 4).
When the fetal brain sections were PFA-fixed on the 
slide, intense deposition of human IgG was observed in 
the fetal vessels [co-labeled with anti-von Willebrand fac-
tor (VWF) antibody], choroid plexus, and the periventricu-
lar zones in both experimental groups (Fig. 3b, panel i), as 
expected from circulation of the IgG. However, there was 
greater deposition of human IgG in the perivascular areas 
of the CASPR2-IgG than in the HC-IgG exposed fetuses 
suggesting that some might be bound in  situ (Fig.  3b, 
panel ii). This was confirmed when adjacent sections were 
washed gently to remove unbound IgG before fixation; in 
CASPR2-IgG—but not HC-IgG exposed brains—human 
IgG was clearly bound in the parenchyma (Fig.  3b, panel 
iii). The lack of detectable bound IgG in three saline-
exposed offspring, on either fixed or unfixed tissue, con-
firmed the specificity of the binding for human IgG 
(Fig. 3b, i–iii).
These observations were quantified by measuring the 
mean fluorescence intensity in the isocortex. Despite some 
variability between sections of the same embryo, the fluo-
rescence intensity in the CASPR2-IgG exposed embryos 
was higher than in the HC-IgG exposed embryos, consider-
ing either the mean fluorescence intensity of all photomi-
crographs [t(33.2) = 4.2, P < 0.0001] or the mean for each 
embryo [t(4)  =  4.54, P  =  0.01; Fig.  3b, panel iv]. Thus, 
IgG remained bound to the brain tissue in the CASPR2-IgG 
exposed. To establish whether this bound IgG was directed 
Fig. 3  Transfer of human IgG/CASPR2-antibodies from maternal to 
fetal circulation and brain parenchyma. a Total human IgG was meas-
ured by western blotting in dams and fetus/pups sera at several ges-
tational time points (1 dam per time point) after injection of human 
IgG daily (15  mg/day; titer 1:6400) from E12.5. Data presented as 
mean ± SEM of three western blot replicates (left panel). CASPR2-
antibody levels in sera from dams and embryos/pups throughout ges-
tation and representative images of the cell-based assay testing for 
CASPR2-antibodies in sera from dam and pups at P0 (human IgG, 
red) (right panel). Scale bar: 25 µm. b i Total human IgG (green), in 
fixed sections of embryonic brain (isocortex), co-localizes with a ves-
sel marker, Von Willebrand factor (VWF, red), in the CASPR2-IgG 
and HC-IgG exposed but not in saline-exposed embryos. Scale bar: 
200 µm. ii Higher magnification showing that human IgG is also vis-
ible beyond the vasculature in the parenchyma of CASPR2-IgG and, 
to a lesser extent, HC-IgG exposed embryos. iii Human IgG is still 
detected in the embryonic parenchyma after gentle wash of unbound 
IgG in the CASPR2-IgG but not in the HC-IgG exposed litter. Scale 
bar: 50 µm. iv Amount of bound human IgG (washed slides) in the 
isocortex, determined by the mean fluorescence intensity analysis of 
embryonic brain sections, showing significantly higher intensity in 
the CASPR2-IgG exposed litter. Data presented as mean ± SEM. c 
Elution of antibodies bound to the parenchyma of E18.5 CASPR2-
IgG and HC-IgG (n = 3 animals/group) was performed as depicted 
in the figure (left panel) and the elution supernatant tested on a live 
human CASPR2 cell-based assay (right panel). CASPR2-antibodies 
were detected in the eluate from CASPR2-IgG but not from HC-IgG 
exposed embryos (anti-human IgG, red). Scale bar: 25 µm
◂
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against CASPR2, acid elution of the bound human IgG 
was performed (n  =  3 animals/group), following a previ-
ously described method [6] (Fig. 3c). CASPR2-antibodies 
were detected in the eluate from CASPR2-IgG but not from 
HC-IgG exposed embryos. However, at this gestational 
age, a reduction in CASPR2 expression was not detected 
in the CASPR2-IgG exposed embryos in comparison with 
HC-IgG exposed embryos by western blotting (Online 
Resource 5).
Neurodevelopmental milestones after intrauterine 
exposure to CASPR2‑IgG (Experiment 3)
For behavioral testing, four dams per treatment group were 
injected daily (two with patient 1 and two with patient 2) 
from E12.5 to E18.5 and allowed to deliver. HC-IgG and 
CASPR2-IgG exposed litters showed no differences in the 
number of surviving pups (U = 6; Z = −0.59; P = 0.69) 
and no obvious gross abnormalities. To ensure that the 
behavioral results were not influenced by different litter 
sizes, which could affect maternal–offspring interactions, 
each litter was randomly culled to 6 mice at P1. Gender of 
the randomly selected pups for study did not differ between 
groups (Fisher’s exact test P = 0.39; Fig. 4a).
There was no difference in weight increase over the 
postnatal period (group  ×  time F(2.8, 127.2)  =  0.27, 
P  =  0.51, Greenhouse–Geisser correction; group 
F(1,46) = 0.28, P = 0.6; Fig. 4b). The maternal retrieval 
test, which assesses maternal-infant interactions, showed 
variation but no differences between groups in the time 
taken by the dam to return all pups to the nest [t(6) = 1.2, 
P  =  0.46], or in the latency to retrieve the first pup 
[t(6) = 0.8, P = 0.29; Fig. 4c]. There were no differences 
in any of the parameters analyzed by the modified Fox 
battery, including physical maturation readouts, neurode-
velopmental reflexes, or the motor coordination perfor-
mance (Fig. 4d); a modest increase in days to reach root-
ing behavior was not significant.
Fig. 4  Neonatal period assessment of mice exposed to CASPR2-
IgG and HC-IgG in utero. a No significant differences in the sur-
vival/gender distribution of CASPR2-IgG versus HC-IgG exposed 
pups. Gender distribution determined after random culling of litters 
to 6 pups/litter. b Total body weight during neonatal development 
of CASPR2-IgG and HC-IgG exposed offspring showed no differ-
ences (n  =  24 pups/group; group P  =  0.6; group  ×  time P  =  0.51, 
repeated-measures  ANOVA). c No effect of treatment on the time 
taken by the mother to return all pups to the nest (P = 0.46, independ-
ent samples t test) or latency to retrieve first pup (P = 0.29, independ-
ent samples t test; n = 4 dams/treatment group). d Neonatal develop-
ment assessed by the modified Fox battery in the readouts of physical 
maturation, neurodevelopmental reflexes, and motor coordination 
tests showed no differences between groups, [4 litters (24 pups)/treat-
ment group]; (P > 0.05, independent samples t test). Data presented 
as mean ± SEM
575Acta Neuropathol (2017) 134:567–583 
1 3
Adult behavior after intrauterine exposure 
to CASPR2‑IgG (Experiment 3)
The mice from Experiment 3 were maintained in their 
cages and studied between ages 4–10 months. There were 
no significant differences in tests of locomotor activity 
(Fig. 5a), motor coordination (accelerating rotarod; Fig. 5b) 
or in anxiety tests (elevated plus-maze and light–dark 
box; Fig.  5c/d), although a trend towards less time spent 
in the light was noted in the CASPR2- IgG exposed mice 
(P = 0.07; Fig. 5c/d).
Social behavior was assessed using two methods at 
6–8 months. In the three-chamber social interaction test, 
both CASPR2-IgG and HC-IgG exposed mice showed a 
preference to spend time exploring the wire cage contain-
ing a novel, unfamiliar mouse compared with an empty 
wire cage, but CASPR2-IgG exposed mice spent signifi-
cantly less time interacting with the mouse than HC-IgG 
Fig. 5  Behavioral testing of adult mice exposed to CASPR2-
IgG and HC-IgG in utero. a Locomotor activity: No differences 
between groups (n = 24 CASPR2-IgG/23 HC-IgG; group P = 0.23; 
time  ×  group P  =  0.91, RMANOVA). b Accelerating rotarod: no 
differences between groups in 2 rotarod sessions (n  =  12/group; 
group P = 0.7; session × group P = 0.27, RMANOVA). c Elevated 
plus-maze: no differences between groups in total distance travelled 
(P = 0.79, independent samples t test), time in open arms (P = 0.87, 
independent samples t test) or entries in open arms (P = 0.89, Mann–
Whitney test; n = 12/group), and test duration: 300 s. d Light–dark 
box: no differences between groups for time in light box (P = 0.07, 
independent samples t test), latency to enter light box (P = 0.46, inde-
pendent samples t test) and number of entries in light box (P = 0.51, 
Mann–Whitney test; n = 12/group), test duration: 300 s. e 3-chamber 
social interaction test: CASPR2-IgG exposed mice spent significantly 
less time in social interaction during the sociability phase (n  =  12/
group; P  =  0.006, independent samples t test), but no differences 
were found during the social memory phase (P = 0.22, independent 
samples t test). Sociability index was calculated as (the time spent in 
the interaction zone around the stimulus animal) divided by (the time 
spent in the interaction zone around the stimulus animal plus the time 
spent in the analogous zone of the empty chamber), and values pre-
sented as a percentage. Social memory index was calculated as (the 
time spent in the interaction zone around the novel animal) divided 
by (the time spent in the interaction zone around the novel animal 
plus the time spent in the analogous zone of the known animal), 
and values presented as a percentage. f Reciprocal social interaction 
test: CASPR2-IgG exposed mice engaged in less social interaction 
(P = 0.008; Mann–Whitney test) and spent more time in non-social 
activities (grooming/digging) than HC-IgG exposed mice (n  =  15 
pairs CASPR2-IgG/6 pairs HC-IgG; P = 0.04; Mann–Whitney test). 
g Olfaction test: no differences between groups in the preference for 
a novel odor, determined by percentage of time spent with the novel/
familiar odor (P = 0.78, independent samples t test) or percentage of 
entries in the novel/familiar odor interaction zone (P = 0.95, Mann–
Whitney test). h Nesting test: CASPR2-IgG exposed mice show 
decreased nesting behavior (12/group,  P  =  0.03; Mann–Whitney 
test). i T-maze spontaneous alternation: marginal effect with reduced 
alternation in the CASPR2-IgG exposed group (n  =  24 CASPR2-
IgG/23 HC-IgG, P  =  0.067, independent samples t test). Data pre-
sented as mean ± SEM, except number of entries in open arms, num-
ber of entries in light box, and reciprocal interaction test presented as 
median with interquartile range; * P < 0.05; ** P < 0.01
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exposed mice [t(22) = 3.086, P = 0.006; raw data avail-
able in Online Resource 6]. When subsequently given a 
choice between the same mouse and a new mouse, both 
CASPR2-IgG and HC-IgG exposed mice preferentially 
explored the novel animal suggesting no social memory 
deficits [t(22)  =  1.253, P  =  0.223; Fig.  5e]. Using the 
reciprocal social interaction test, CASPR2-IgG exposed 
mice were again found to spend less time engaged in 
active social interaction (sniffing, licking, mounting, or 
crawling under or over the other mouse; Fig. 5f) than the 
HC-IgG exposed mice (U = 11, Z = −2.647, P = 0.008), 
confirming a significant deficit in social interaction in 
those mice exposed to CASPR2-IgG in utero.
Importantly, there were no differences between groups 
in measures of locomotor activity during the period 
of habituation to the testing arena, ensuring that the 
decrease in social interaction was not due to differences 
in exploratory behavior or habituation to the testing envi-
ronment (Online Resource 7). Furthermore, there were no 
differences in an olfactory test, with both groups show-
ing an equivalent preference for a novel odor compared to 
a recently experienced, and thus familiar, odor (Fig. 5g). 
In addition, there were no differences between groups in 
the time spent exploring the odor area during the sample 
phase of this test [t(14) = 0.55, P = 0.6; data not shown]; 
these results confirmed that the social deficits observed 
were not due to reduced olfaction or response to novelty.
Non-social behaviors (grooming, digging) were 
also assessed during the reciprocal interaction test. 
CASPR2-IgG exposed mice spent more time engaged 
in those activities than HC-IgG exposed mice [U  =  19, 
Z  =  −2.024, P  =  0.04; Fig.  5f, right panel]. In a nest-
building test, a species-typical behavior claimed to be 
potentially relevant to home–cage social interaction [23], 
CASPR2-IgG exposed mice scored less than the HC-
IgG exposed animals [U  =  39, Z  =  −2.126, P  =  0.03; 
Fig. 5h]. All mice were also tested for spontaneous alter-
nation in the T-maze, a test of short-term memory, and a 
trend towards a decrease in alternation was noted in the 
CASPR2-IgG exposed mice [t(45) = −1.874, P = 0.067; 
Fig.  5i]; this is of potential relevance considering that 
Cntnap2 knockout mice were found to alternate less in 
the same test [23].
The results from all behavior tests were first analyzed 
without separating the genders. On further analysis (Online 
Resource 8), we found no gender effect in any of the behav-
ioral parameters analyzed, with the exception of the nest-
ing test [H(3) = 9.6, P = 0.02; Kruskal–Wallis test], which 
showed lower scores in CASPR2-IgG exposed males 
(U = 33, P = 0.01; Mann–Whitney test) but not in females 
(U  =  18, P  =  1.0; Mann–Whitney test). A trend towards 
a gender effect was also noted for the light–dark test and 
the time spent in non-social activities during the reciprocal 
social interaction test, with male CASPR2-IgG mice being 
more affected.
Adult mice after intrauterine exposure to CASPR2‑IgG 
show abnormal lamination of the somatosensory cortex 
(Experiment 3)
At 12  months, coded brains from 3 to 6 animals in each 
group were randomly selected for histological analysis. 
In particular, since abnormalities of neuronal migration 
were reported in this brain region in the  Cntnap2  knock-
out model [23], the somatosensory cortex was evaluated 
for the presence of alterations in normal cortical structure. 
No gross morphological abnormalities and no morphomet-
ric differences were observed in the overall thickness of the 
cortex or in the thickness of the upper, middle, and deep 
layers, as assessed by Nissl staining (Fig. 6a).
Laminar position patterns, analyzed by assessing 
FOXP2-positive (marker of layer VI) neurons, did not 
reveal any differences between CASPR2-IgG and HC-IgG 
exposed groups (data not shown). However, there was an 
increase in the density of CUX1-positive cells (marker of 
layers II–IV) in layers V/VI in CASPR2-IgG exposed ani-
mals [t(4) = 3.63, P = 0.02], suggesting a neuronal migra-
tion defect (Fig. 6b).
To determine which neurons were expressing CUX1 
in layers V/VI, the GABAergic and glutamatergic mark-
ers GAD65/67 and glutaminase, respectively, were used. 
In both CASPR2-IgG and HC-IgG exposed animals, most 
CUX1-positive neurons in layers V/VI were glutamatergic 
and none were identified as GABAergic (Fig. 6c).
There were no morphometric differences between 
groups with respect to the prefrontal cortices (anterior 
cingulate, prelimbic, and infralimbic cortices), corpus cal-
losum, hippocampus or cerebellum, and no gross morpho-
logical abnormalities or neuronal ectopias/misalignments 
were detected in any of these brain areas (Online Resource 
9 to 13).
Adult mice after intrauterine exposure to CASPR2‑IgG 
display increased densities of microglia and microglia 
with an activated morphological phenotype 
(Experiment 3)
CD68/Iba1-positive cells (defining activated micro-
glia) were quantified in the prelimbic, infralimbic, and 
somatosensory cortices. All P values below are adjusted 
according to the Holm–Sidak correction for multi-
ple comparisons. There was an average 16% increase 
in mean Iba1/CD68-positive microglial densities in 
the CASPR2-IgG exposed animals, across all layers 
of the studied areas (Fig.  7a, b). In the prelimbic cor-
tex, there was an increase in CASPR2-IgG exposed 
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mice in all layers [layer I: t(12) = 2.2, P = 0.049; layers 
II–IV: t(12) = 4.3; P = 0.0032, layer V–VI: t(12) = 4.1; 
P  =  0.0032), as also in the infralimbic cortex [layer 
I: t(12)  =  3.5, P  =  0.0095; layers II–III: t(12)  =  3.0, 
P = 0.01; layers V–VI: t(12) = 5.2, P = 0.0007]. In the 
somatosensory cortex, the same trend was observed in 
all layers, statistically significant in layers I and II–IV 
[layer I: t(12) = 3.4, P = 0.014; layers II–IV: t(12) = 3.4, 
P  =  0.014; layer V–VI: t(12)  =  2.1, P  =  0.054]. The 
results in embryos at E18.5 (Exp 2) were variable but 
showed a similar trend towards increased CD68-positive 
microglia (P = 0.01 uncorrected; Online Resource 14).
A detailed morphological analysis of parameters 
of microglial activation (number of ramifications and 
soma size) was performed in IBA-1-positive cells from 
the somatosensory cortex in both groups (n = 101 cells/
group; 30–40 cells/animal; 3 animals/group) (Fig.  7c). 
Microglia in CASPR2-IgG exposed animals were sig-
nificantly less ramified (U  =  3.8; P  =  0.001) and had 
increased soma size (U  =  6.2; P  =  0.014), consistent 
with an activated phenotype (Fig. 7d).
Adult mice after intrauterine exposure to CASPR2‑IgG 
display decreased densities of glutamatergic synaptic 
profiles in the prefrontal and somatosensory cortices 
(Experiment 3)
It is well established that microglia play a role in synap-
tic pruning [22]. We identified the post-synaptic density 
of glutamatergic synapses using PSD95, confirmed by 
its association with the presynaptic terminal marker syn-
aptophysin (Online Resource 15), and used a robust ste-
reological sampling method to provide a large number 
of PSD95-positive profiles per layer (>2000 profiles). 
Our method covered a sufficient volume of each corti-
cal layer to ensure sufficient sampling of the irregularly 
spaced PSD95-positive puncta in the neuropil and thus 
provided an accurate assessment of mean synaptic puncta 
density. We found a 15–52% reduction in the number of 
PSD95-positive synaptic profiles across the prelimbic, 
infralimbic, and somatosensory cortices in the CASPR2-
IgG exposed animals (Fig.  8a, b). In the prelimbic cor-
tex, the PSD95-positive synaptic profiles were reduced in 
Fig. 6  Lamination patterns of the somatosensory cortex. a Rep-
resentative image of the histological boundaries used to define the 
different somatosensory cortical layers (left) and cortical thick-
ness measurements (right), showing no differences found between 
CASPR2-IgG and HC-IgG exposed animals (n = 6 brains/group). b 
Representative images of the CUX1 (red) staining across treatment 
groups at low (i; Scale bar: 200 µm) and high magnification (ii; scale 
bar: 50 µm), focusing on layers V/VI (left). Quantification of CUX1-
positive cells in layers V/VI of the somatosensory cortex (right) 
showing statistically significant increase in CUX1-positive cells in 
layers V–VI in CASPR2-IgG versus HC-IgG exposed animals (n = 3 
brains/group). c Representative images of the i CUX1 (red)/glutami-
nase (green) and ii CUX1 (red)/GAD 65/67 (green) staining of neu-
rons in layers V–VI in the somatosensory cortex. Scale bars: 50 µm. 
All data presented as mean ± SEM; *P < 0.05
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layers I and II–III [layer I: t(12) = 7.0, P = 0.00004; lay-
ers II–III: t(12)  =  4.9, P  =  0.0007], with a strong trend 
in the deep layers [layer V–VI: t(12)  =  2.1, P  =  0.055]. 
In the infralimbic cortex, a significant decrease was 
seen in all layers [layer I: t(12) = 5.1, P = 0.0005; layers 
II–III t(12) = 7.3, P = 0.00003; layer V–VI t(12) = 4.1, 
P = 0.001], and also in the somatosensory cortex [layer I: 
t(12) = 3, P = 0.02; layers II–IV: t(12) = 4.5, P = 0.002; 
layer V–VI: t(12) = 2.2, P = 0.049]. These results demon-
strate increased microglia and reduced glutamatergic syn-
aptic profiles in the CASPR2-IgG exposed mice that were 
apparent as late as 12 months after birth.
Consistent with a decrease in glutamatergic synaptic pro-
files, CASPR2-IgG exposed mice had a significant reduc-
tion in the density of GluA1 profiles in the somatosensory 
cortex [t(12)  =  4.2; P  =  0.0036]. Both synaptic (GluA1/
PSD95-positive puncta) and extra-synaptic (GluA1-pos-
itive/PSD95-negative puncta) GluA1 were numerically 
reduced in the CASPR2-IgG exposed mice, but this differ-
ence was significant only for extra-synaptic GluA1 profiles 
[t(12)  =  2.9; P  =  0.028] (Fig.  8 c, d). GluA1 expression 
was also examined in the embryos at E18.5, but, at this 
stage, no differences in total GluA1 expression were found 
between groups by western blotting (Online Resource 16).
Despite the reduction in synaptic profiles, the numbers of 
NeuN-positive neurons in the medial prefrontal cortex (pre-
limbic and infralimbic cortices) were not different between 
CASPR2-IgG and HC-IgG exposed animals (Fig. 8e, f). In 
the somatosensory cortex, there was a modest decrease in 
the neuronal densities in layer II–IV (P = 0.02), but not in 
layer I (P = 0.8) or layer V–VI (P = 0.1).
Discussion
CASPR2-antibodies are now well recognized in patients 
with autoimmune forms of neurological disease, but have 
also been reported in a small subgroup of mothers (with-
out any signs of overt disease) whose progeny were diag-
nosed with neurodevelopmental disorders [5, 8]. To clarify 
whether this association was related to CASPR2-antibodies 
or to other inflammatory/immune factors, we investigated 
how CASPR2-antibodies might mediate effects on the fetal 
brain using a previously established protocol for maternal-
to-fetal transfer [15]. We injected patient IgG containing 
CASPR2-antibodies into pregnant mice and examined the 
offspring throughout the first year of life and post-mortem, 
comparing with IgG from healthy individuals. The mice 
Fig. 7  Activated microglia densities and morphological analysis. a 
Representative images of the somatosensory cortex showing micro-
glial staining (DAPI, blue; CD68, green; Iba1, red). i: 25 µm. b Quan-
tification of CD68/Iba1-positive microglial densities in the prelimbic, 
infralimbic, and somatosensory cortices (n = 3 brains/group). c Rep-
resentative images of z-stack projections of Iba1-positive microglia 
used for morphological analysis. d Microglia morphological char-
acterization: number of ramifications and soma size (n = 101 cells/
group; 30–40 cells/animal; 3 animals/group). *P < 0.05; **P < 0.01; 
***P < 0.001. All data presented as mean ± SEM
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exposed in utero to CASPR2-antibodies had positive serum 
levels and CASPR2-antibodies were bound to brain tissue, 
but neonatal behaviors were not affected. However, when 
examined as adults, the mice  demonstrated altered social 
behavior accompanied by neuronal ectopias, reduced num-
bers of glutamatergic synaptic profiles, and increased den-
sities of microglia with an activated morphology. Thus, 
this mouse study establishes that maternal autoantibod-
ies to a CNS protein can cause long-term brain pathology 
and behavioral deficits. CASPR2-antibodies that we found 
raised in mothers of affected children [8] could contribute 
to neurodevelopmental deficits.
CASPR2 plays an important role during neurodevelop-
ment [33], as demonstrated in vitro [1, 34] and in vivo [23]. 
A homozygous deletion of CNTNAP2 in the mouse resulted 
in social deficits associated with disorganization of the lam-
ination of the somatosensory cortex, aberrant arborization 
of dendrites, and maturation of dendritic spines with con-
sequences for neuronal network activity. Other features of 
the Cntnap2 knockout mouse, such as motor hyperactivity 
and hyper-reactivity to peripheral sensory stimuli, share 
some features with the immunotherapy-responsive periph-
eral nerve hyperexcitability and pain in adult patients with 
acquired CASPR2-antibodies [14]. Thus, in utero exposure 
to CASPR2-antibodies can lead to permanent changes in 
brain histology and behavior similar to those in the CNT-
NAP2 disrupted mice, but do not reproduce the reversible, 
partly peripheral phenotype seen when adults are exposed 
to the same antibodies.
During the final stages of this study, others [5] also 
described CASPR2-antibodies in mothers of children with 
neurodevelopmental disorders, and studied a similar mater-
nal-to-fetal transfer using a monoclonal CASPR2-antibody 
derived from one mother of a child with autism. They 
identified an ASD-phenotype, similar to that we observed 
here, but only in the male offspring of dams. We did not 
find a strong gender effect in our mice, although a trend to 
more affected males was observed in a few tests. It is pos-
sible that the differences between the gender results relate 
to the injected CASPR2-antibodies (a single injection of 
Fig. 8  PSD95 and GluA1 profiles, and neuronal densities. a Quan-
tification of PSD95-positive puncta in the prelimbic, infralimbic, 
and somatosensory cortices (n  =  3 brains/group). b Representative 
images of the somatosensory cortex showing synaptic profile stain-
ing (PSD95, green; DAPI, blue). Scale bar 10 µm. c Representative 
images of the somatosensory cortex showing GluA1 and PSD95 
staining (GluA1, green; PSD95, red; DAPI, blue). Scale bar 15 µm. d 
Quantification of Total GluA1 profiles, and synaptic (GluA1/PSD95-
positive) and extra-synaptic (GluA1-positive/PSD95-negative) 
profiles in the somatosensory cortex. e Quantification of neuronal 
densities in the prelimbic, infralimbic, and somatosensory cortices 
(n = 3 brains/group). f Representative images of the somatosensory 
cortex showing neuronal staining (NeuN, red; DAPI, blue). Scale 
bar = 50 µm. *P < 0.05; **P < 0.01; ***P < 0.001. All data pre-
sented as mean ± SEM
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monoclonal antibody at E13.5 compared with daily injec-
tions of polyclonal patients’ IgG), timing of behavioral and 
histological assessments, or the choice of mouse strains; we 
deliberately used an outbred strain, Crl:MF1, because of 
their excellent maternal behavior (given the risk of mater-
nal rejection due to early experimental manipulation of 
the pups) and large litters. Overall, our histological find-
ings complement, rather than differ from those of Brim-
berg et al. who detected abnormalities in cortical develop-
ment such as thinned cortical plate and decreased number 
of neural progenitors at E15.5, which might precede the 
abnormalities of cortical lamination we found in our animal 
model. Likewise, they reported a decrease in dendritic tree 
complexity and dendritic spine densities in the hippocam-
pus, detected by Golgi stain, which is compatible with our 
findings of decreased density of glutamatergic synapses 
in the cortex in the adult offspring; in our mice, the hip-
pocampal changes did not reach significance.
Aberrant glutamatergic synapse structure and function 
has been implicated in neurodevelopmental disorders such 
as autism, intellectual disability, and schizophrenia [37]. 
This theory is often based on the study of dendritic spine 
numbers and morphology in human post-mortem studies 
or in animal models of neurodevelopmental disorders [18]. 
Given that 90% of all excitatory synapses occur in dendritic 
spines, this is usually accepted as a useful proxy of syn-
apse pathology. However, the results vary from increased 
spine densities observed in ASD and Fragile X syndrome 
to significantly decreased numbers of spines in Rett’s Syn-
drome, Down’s syndrome, or other forms of intellectual 
disability [24]. Moreover, the numbers and morphology 
of dendritic spines may not fully reflect the maturity of the 
glutamatergic synapse. Discrepancies in results could also 
arise from use of the Golgi method, which stains a very 
restricted population of neurons, thus producing a sampling 
bias. By contrast, here using a specific method that allows 
the quantification of synaptic profiles in a large volume of 
each cortical layer and a marker of mature glutamatergic 
synapses, PSD95 [25], the results pointed clearly towards 
a loss of glutamatergic synapses, with minimal neuronal 
loss, in layers of the medial prefrontal and somatosensory 
cortices in keeping with the role of CASPR2 in the estab-
lishment of stable excitatory synapses [1, 34]. In line with 
the glutamatergic synapse loss, we found a reduction in the 
AMPA receptor subunit GluA1, both total and extra-synap-
tic GluA1, consistent with the role of CASPR2 in GluA1 
trafficking [34].
The inverse association between increased microglial 
densities per layer in the cortical areas examined and the 
associated decrease in synaptic profiles makes a compelling 
case for a role for microglia in pruning excitatory synapses 
in the CASPR2-antibody exposed mice. Synapse elimina-
tion occurs in the healthy developing brain and microglia 
are implicated as the key cellular players of this comple-
ment-mediated synaptic pruning. The microglia engulf 
synaptic material, a process that is partly mediated by the 
microglial C3 receptor and its ligand, the complement com-
ponent C3 [22, 30] [32]. Supporting a role for microglia-
dependent pruning in neurodevelopmental disorders, mice 
with decreased synaptic pruning due to genetic knock-
out of the chemokine receptor CX3CR1 (a crucial recep-
tor for neuron-microglia signaling) displayed deficits in 
social interaction and increased repetitive behaviors [41]. 
However, this is, to our knowledge, the first link between 
activated microglia, synaptic defects, and any maternal 
autoantibody.
The most striking behavioral abnormalities identified 
were deficits in social interaction. These are usually inter-
preted in the literature as the hallmark of an autism-like 
phenotype, but in our study of gestational human cohorts 
[8], maternal CASPR2-antibodies were associated with 
mental retardation, speech and language impairments, and 
other undefined neurodevelopmental disorders, but not with 
autism per se. One must note, nevertheless, that impair-
ment of social skills and stereotypies are symptomatic 
features common to patients with a range of neurodevelop-
mental disorders [7].
One can only speculate about the mechanisms by which 
CASPR2-antibodies cause changes in neurodevelopment. 
As discussed above, it is possible that mice exposed to 
these antibodies have an increased number of aberrant or 
weaker synapses that are then targeted for elimination. 
Alternatively, the antibodies may have bound directly to 
synapses to tag them for elimination by complement dur-
ing development. Another major question relates to the per-
sistence of microglia activation after an initial insult that 
occurs during development. It is now well accepted that 
an excess of reactive microglia is seen in the neuropathol-
ogy of patients with different neurodevelopmental and neu-
ropsychiatric disorders [35, 39, 40], but the mechanisms 
remain unclear.
There are also questions regarding how human IgG 
reaches the brain parenchyma to cause these remark-
ably long-term effects. Consistent with our previous data 
[15], human IgG was found to transfer from dam to fetus 
throughout the last 6 days of gestation and to achieve 
levels of IgG and CASPR2-antibodies that were easily 
detectable in the embryos, and in the mice culled shortly 
after birth. Although CASPR2-antibodies were not at 
very high titer, the levels were similar to those we found 
in maternal samples [8]. Moreover, since transport in 
rodents is predominantly via lactation [2], in Experiment 
3, lactation could have contributed to CASPR2-antibody 
exposure, while the levels remained high in the dams. 
The evidence of diffusion of IgG from the embryonic 
vasculature into the brain tissue that we found, despite 
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the presence of a blood–brain barrier in the developing 
mouse [29], is similar to that shown using monoclonal 
antibodies to NR2a/2b subunits of the NMDA receptor in 
an active immunization protocol [16], and it is possible 
that the bound IgG may be sequestered in the parenchyma 
as recently proposed in humans and adult animals [6].
There are some limitations to this study. First, due to 
the lack of availability of maternal samples and need for 
large volumes of the injected material, we used IgG from 
two patients with CASPR2 encephalitis rather than IgG 
from mothers of children with neurodevelopmental disor-
ders; it is possible that the CASPR2-antibodies in the two 
patients target different epitopes to those found in the moth-
ers’ samples we previously examined [8]. Second, although 
we excluded the presence of other antibodies by binding to 
CASPR2-null brain tissue, it is still possible that low levels 
of other brain-reactive antibodies could have been present, 
but undetected, in the IgG preparations. Nevertheless, the 
phenotype similarities between our model and that using a 
CASPR2 monoclonal antibody derived from the mother of 
one child with autism [4] support our conclusion that the 
effects of the IgG preparations were due to the presence 
of the CASPR2-antibodies rather than other brain-reactive 
IgGs. Third, in a maternal-to-fetal transfer model, both dam 
and embryo are exposed to the pathogenic antibodies; it 
is possible that an effect of the human IgG on the dams’ 
maternal behavior could have influenced the  development 
of the offspring. However, the adult blood–brain barrier is, 
under normal circumstances, only very slightly permeable 
to IgG, whereas others have shown [3] as we have here, that 
IgG can be found in the fetal brain parenchyma after trans-
fer from the pregnant dam. It is possible that there were 
minor effects of the injected CASPR2-IgG on the maternal 
cognition or behavior, but this was not evident from obser-
vation of the dams themselves, nor in the lack of differ-
ences between the groups in neonatal milestones or physi-
cal maturation readouts, or in the maternal retrieval test.
Despite these limitations, our findings support a model 
in which maternal antibodies towards fetal cell-surface neu-
ronal proteins can cause long-term behavioral deficits and 
permanent abnormalities at the cellular and synaptic lev-
els in a small subset of children with neurodevelopmental 
disorders. The exact pathophysiological mechanisms by 
which CASPR2-antibodies affect brain development dur-
ing the fetal period need further study, and how these result 
in such striking and persistent microglial and synaptic 
changes. These questions and the search for other maternal 
neuronal-surface antibodies indicate just some of the many 
avenues for further studies. Importantly, the identification 
of specific pathogenic antibodies in mothers of children 
with neurodevelopmental disorders could allow the identi-
fication of at-risk children, facilitating diagnosis and early 
intervention, and could also lead to treatment or preventive 
measures during the pregnancy, in keeping with the current 
practice in other antibody-mediated neonatal disorders.
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